International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-3
Original Article
Clinical Profile and Outcome of Leptospirosis in Tertiary Care Center Karwar, UK District
 ,
Published
May 25, 2024
Abstract

Background: Leptospirosis remains a vital health concern in tropical regions, with varying clinical presentations, complications, and outcomes. This study offers a comprehensive insight into leptospirosis diagnosed at the Karwar Institute of Medical Sciences.

Methods: A retrospective analysis of 50 patients diagnosed between January 2020 and December 2021 was conducted. Clinical manifestations, laboratory parameters, complications, and outcomes were documented and analyzed.

Results: Predominance was observed among 21-40 year-olds (50%) and males (70%). Major exposure routes included water-related activities (40%), animal contact (30%), and agricultural work (20%). Clinical presentation primarily comprised fever (90%), muscle pain (80%), and jaundice (50%). Laboratory diagnostics revealed an average ELISA titer of 1:800 and a slightly elevated mean WBC count of 11.2 x10^9/L. Renal failure emerged as a significant complication (20%). Patient outcomes depicted 64% recovering without complications, while 2% mortality was recorded. Multivariate analysis identified age above 40, jaundice at presentation, and thrombocytopenia as potent risk factors for severe complications.

Conclusion: Leptospirosis in the Karwar region presents unique demographic and clinical patterns. While the findings echo global trends in many respects, distinct regional characteristics necessitate tailored interventions. Comprehensive awareness, early diagnosis, and targeted treatment strategies are imperative to manage and mitigate the disease's impact effectively.

Recommended Articles
Loading Image...
Volume-5, Issue-3
Citations
1633 Views
445 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved